Image: MenoLabs

Dr. Reddy’s Laboratories, a global pharmaceutical company headquartered in India, has acquired MenoLabs, a women’s health and dietary supplement brand, as part of Amyris Chapter 11 sales process. This acquisition was conducted through an auction, with Dr. Reddy’s successfully bidding $3 million for the women’s supplements label according to court documents.

MenoLabs’ portfolio, now a part of Dr. Reddy’s offerings, includes seven branded products designed to support health and address symptoms of perimenopause and menopause. The supplements are sold primarily in the United States through MenoLabs’ website and other e-commerce platforms such as Amazon and Walmart. The acquisition also includes the MenoLife health tracker app.

“The MenoLabs acquisition will serve as a catalyst to accelerate growth in this space and build upon our aspiration to lead in the fast-growing women’s nutritional and wellness markets,” says Marc Kikuchi, Chief Executive Officer for Dr. Reddy’s in North America. “The acquisition complements Dr. Reddy’s U.S. self-care and wellness business portfolio of brands and addresses unmet needs of consumers for science-based, research-driven products that provide relief from the symptoms of menopause. For these and many other reasons, I believe we are well-positioned to successfully integrate and grow the business.”

Dr. Reddy’s, headquartered in Hyderabad, India, is known for its extensive product and service offerings, including APIs, generics, branded generics, biosimilars, and OTC products, covering various therapeutic areas. Amyris, a biotech beauty company, filed for voluntary Chapter 11 bankruptcy in August 2023 and proceeded to auction off four consumer brands, including MenoLabs. The auction resulted in various acquisitions, including the ‘clean’ skincare label Biossance by the US business of Lookfantastic and Cult Beauty owner THG Beauty for $20M, baby care brand Pipette by HRB Brands for $1.75M, and actress Tia Mowry’s hair care brand 4U by Scent Theory Products for $600K.

Show CommentsClose Comments

Leave a comment